These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
87 related articles for article (PubMed ID: 18294849)
1. Synthesis and SAR of 1-acetanilide-4-aminopyrazole-substituted quinazolines: selective inhibitors of Aurora B kinase with potent anti-tumor activity. Foote KM; Mortlock AA; Heron NM; Jung FH; Hill GB; Pasquet G; Brady MC; Green S; Heaton SP; Kearney S; Keen NJ; Odedra R; Wedge SR; Wilkinson RW Bioorg Med Chem Lett; 2008 Mar; 18(6):1904-9. PubMed ID: 18294849 [TBL] [Abstract][Full Text] [Related]
2. Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of aurora B kinase. Mortlock AA; Foote KM; Heron NM; Jung FH; Pasquet G; Lohmann JJ; Warin N; Renaud F; De Savi C; Roberts NJ; Johnson T; Dousson CB; Hill GB; Perkins D; Hatter G; Wilkinson RW; Wedge SR; Heaton SP; Odedra R; Keen NJ; Crafter C; Brown E; Thompson K; Brightwell S; Khatri L; Brady MC; Kearney S; McKillop D; Rhead S; Parry T; Green S J Med Chem; 2007 May; 50(9):2213-24. PubMed ID: 17373783 [TBL] [Abstract][Full Text] [Related]
3. Discovery of novel and potent thiazoloquinazolines as selective Aurora A and B kinase inhibitors. Jung FH; Pasquet G; Lambert-van der Brempt C; Lohmann JJ; Warin N; Renaud F; Germain H; De Savi C; Roberts N; Johnson T; Dousson C; Hill GB; Mortlock AA; Heron N; Wilkinson RW; Wedge SR; Heaton SP; Odedra R; Keen NJ; Green S; Brown E; Thompson K; Brightwell S J Med Chem; 2006 Feb; 49(3):955-70. PubMed ID: 16451062 [TBL] [Abstract][Full Text] [Related]
4. Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines. Payton M; Bush TL; Chung G; Ziegler B; Eden P; McElroy P; Ross S; Cee VJ; Deak HL; Hodous BL; Nguyen HN; Olivieri PR; Romero K; Schenkel LB; Bak A; Stanton M; Dussault I; Patel VF; Geuns-Meyer S; Radinsky R; Kendall RL Cancer Res; 2010 Dec; 70(23):9846-54. PubMed ID: 20935223 [TBL] [Abstract][Full Text] [Related]
5. GSK1070916, a potent Aurora B/C kinase inhibitor with broad antitumor activity in tissue culture cells and human tumor xenograft models. Hardwicke MA; Oleykowski CA; Plant R; Wang J; Liao Q; Moss K; Newlander K; Adams JL; Dhanak D; Yang J; Lai Z; Sutton D; Patrick D Mol Cancer Ther; 2009 Jul; 8(7):1808-17. PubMed ID: 19567821 [TBL] [Abstract][Full Text] [Related]
6. NMS-P937, a 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivative as potent and selective Polo-like kinase 1 inhibitor. Beria I; Bossi RT; Brasca MG; Caruso M; Ceccarelli W; Fachin G; Fasolini M; Forte B; Fiorentini F; Pesenti E; Pezzetta D; Posteri H; Scolaro A; Re Depaolini S; Valsasina B Bioorg Med Chem Lett; 2011 May; 21(10):2969-74. PubMed ID: 21470862 [TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, and biological evaluation of pyrazolopyrimidine-sulfonamides as potent multiple-mitotic kinase (MMK) inhibitors (part I). Zhang L; Fan J; Chong JH; Cesena A; Tam BY; Gilson C; Boykin C; Wang D; Aivazian D; Marcotte D; Xiao G; Le Brazidec JY; Piao J; Lundgren K; Hong K; Vu K; Nguyen K; Gan LS; Silvian L; Ling L; Teng M; Reff M; Takeda N; Timple N; Wang Q; Morena R; Khan S; Zhao S; Li T; Lee WC; Taveras AG; Chao J Bioorg Med Chem Lett; 2011 Sep; 21(18):5633-7. PubMed ID: 21798738 [TBL] [Abstract][Full Text] [Related]
8. 3-Cyano-6-(5-methyl-3-pyrazoloamino)pyridines: selective Aurora A kinase inhibitors. Ando R; Ikegami H; Sakiyama M; Ooike S; Hayashi M; Fujino Y; Abe D; Nakamura H; Mishina T; Kato H; Iwase Y; Tomozane H; Morioka M Bioorg Med Chem Lett; 2010 Aug; 20(15):4709-11. PubMed ID: 20573509 [TBL] [Abstract][Full Text] [Related]
9. Enhancement of radiation response in p53-deficient cancer cells by the Aurora-B kinase inhibitor AZD1152. Tao Y; Zhang P; Girdler F; Frascogna V; Castedo M; Bourhis J; Kroemer G; Deutsch E Oncogene; 2008 May; 27(23):3244-55. PubMed ID: 18084327 [TBL] [Abstract][Full Text] [Related]
10. Synthesis, SAR and biological evaluation of 1,6-disubstituted-1H-pyrazolo[3,4-d]pyrimidines as dual inhibitors of Aurora kinases and CDK1. Le Brazidec JY; Pasis A; Tam B; Boykin C; Black C; Wang D; Claassen G; Chong JH; Chao J; Fan J; Nguyen K; Silvian L; Ling L; Zhang L; Choi M; Teng M; Pathan N; Zhao S; Li T; Taveras A Bioorg Med Chem Lett; 2012 Mar; 22(5):2070-4. PubMed ID: 22326168 [TBL] [Abstract][Full Text] [Related]
12. Discovery of a potent and selective aurora kinase inhibitor. Oslob JD; Romanowski MJ; Allen DA; Baskaran S; Bui M; Elling RA; Flanagan WM; Fung AD; Hanan EJ; Harris S; Heumann SA; Hoch U; Jacobs JW; Lam J; Lawrence CE; McDowell RS; Nannini MA; Shen W; Silverman JA; Sopko MM; Tangonan BT; Teague J; Yoburn JC; Yu CH; Zhong M; Zimmerman KM; O'Brien T; Lew W Bioorg Med Chem Lett; 2008 Sep; 18(17):4880-4. PubMed ID: 18678489 [TBL] [Abstract][Full Text] [Related]
13. Biological characterization of TAK-901, an investigational, novel, multitargeted Aurora B kinase inhibitor. Farrell P; Shi L; Matuszkiewicz J; Balakrishna D; Hoshino T; Zhang L; Elliott S; Fabrey R; Lee B; Halkowycz P; Sang B; Ishino S; Nomura T; Teratani M; Ohta Y; Grimshaw C; Paraselli B; Satou T; de Jong R Mol Cancer Ther; 2013 Apr; 12(4):460-70. PubMed ID: 23358665 [TBL] [Abstract][Full Text] [Related]
14. PF-03814735, an orally bioavailable small molecule aurora kinase inhibitor for cancer therapy. Jani JP; Arcari J; Bernardo V; Bhattacharya SK; Briere D; Cohen BD; Coleman K; Christensen JG; Emerson EO; Jakowski A; Hook K; Los G; Moyer JD; Pruimboom-Brees I; Pustilnik L; Rossi AM; Steyn SJ; Su C; Tsaparikos K; Wishka D; Yoon K; Jakubczak JL Mol Cancer Ther; 2010 Apr; 9(4):883-94. PubMed ID: 20354118 [TBL] [Abstract][Full Text] [Related]
15. SAR and inhibitor complex structure determination of a novel class of potent and specific Aurora kinase inhibitors. Heron NM; Anderson M; Blowers DP; Breed J; Eden JM; Green S; Hill GB; Johnson T; Jung FH; McMiken HH; Mortlock AA; Pannifer AD; Pauptit RA; Pink J; Roberts NJ; Rowsell S Bioorg Med Chem Lett; 2006 Mar; 16(5):1320-3. PubMed ID: 16337122 [TBL] [Abstract][Full Text] [Related]
16. Localization of human TACC3 to mitotic spindles is mediated by phosphorylation on Ser558 by Aurora A: a novel pharmacodynamic method for measuring Aurora A activity. LeRoy PJ; Hunter JJ; Hoar KM; Burke KE; Shinde V; Ruan J; Bowman D; Galvin K; Ecsedy JA Cancer Res; 2007 Jun; 67(11):5362-70. PubMed ID: 17545617 [TBL] [Abstract][Full Text] [Related]
17. Structure-based drug design: Synthesis and biological evaluation of quinazolin-4-amine derivatives as selective Aurora A kinase inhibitors. Long L; Wang YH; Zhuo JX; Tu ZC; Wu R; Yan M; Liu Q; Lu G Eur J Med Chem; 2018 Sep; 157():1361-1375. PubMed ID: 30196060 [TBL] [Abstract][Full Text] [Related]
18. Development and biological evaluation of a novel aurora A kinase inhibitor. Sardon T; Cottin T; Xu J; Giannis A; Vernos I Chembiochem; 2009 Feb; 10(3):464-78. PubMed ID: 19199284 [TBL] [Abstract][Full Text] [Related]
19. Imidazo[4,5-b]pyridine derivatives as inhibitors of Aurora kinases: lead optimization studies toward the identification of an orally bioavailable preclinical development candidate. Bavetsias V; Large JM; Sun C; Bouloc N; Kosmopoulou M; Matteucci M; Wilsher NE; Martins V; Reynisson J; Atrash B; Faisal A; Urban F; Valenti M; de Haven Brandon A; Box G; Raynaud FI; Workman P; Eccles SA; Bayliss R; Blagg J; Linardopoulos S; McDonald E J Med Chem; 2010 Jul; 53(14):5213-28. PubMed ID: 20565112 [TBL] [Abstract][Full Text] [Related]
20. The selective Aurora B kinase inhibitor AZD1152 as a novel treatment for hepatocellular carcinoma. Aihara A; Tanaka S; Yasen M; Matsumura S; Mitsunori Y; Murakata A; Noguchi N; Kudo A; Nakamura N; Ito K; Arii S J Hepatol; 2010 Jan; 52(1):63-71. PubMed ID: 19913935 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]